BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sotiburafusp alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sotiburafusp alfa\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07376629-2128@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Sotiburafusp alfa: Phase 2 readout est. (NCT07376629)
DESCRIPTION:Sotiburafusp alfa\, phase 2.\nStudy: A Study of HB0025 Plus Nab
 -paclitaxel as First Line Therapy for TNBC\nEstimated primary completion: 
 15 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/soti
 burafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07376629
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07360132-2128@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Sotiburafusp alfa: Phase 3 readout est. (NCT07360132)
DESCRIPTION:Sotiburafusp alfa\, phase 3\, Non-Small Cell Lung Cancer.\nStud
 y: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pe
 mbrolizumab Combined With Chemotherapy for the First-Line Treatment of Adv
 anced Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: 1
 0 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotibur
 afusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07360132
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383116-2128@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Sotiburafusp alfa: Phase 3 readout est. (NCT07383116)
DESCRIPTION:Sotiburafusp alfa\, phase 3\, Non-Small Cell Lung Cancer.\nStud
 y: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Ti
 slelizumab Combined With Chemotherapy as First-Line Treatment for Advanced
  Nonsquamous Non-Small Cell Lung Cancer\nEstimated primary completion: 10 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotiburaf
 usp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07383116
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902999-2128@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20290423
DTEND;VALUE=DATE:20290424
SUMMARY:Sotiburafusp alfa: Phase 3 readout est. (NCT07902999)
DESCRIPTION:Sotiburafusp alfa\, phase 3\, Endometrial Cancer.\nStudy: HB002
 5-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as Firs
 t-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Canc
 er\nEstimated primary completion: 23 April 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07902999
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
